CD226 and neoplasm: Benefits include the possibility to use haplo healthy donors as a source of NK cells without significant GVH, and the constitutive surface expression of activating NK receptors (NCR, NKG2D, DNAM-1) recognizing tumor antigens and co-operating with CARs [19,182].